Posted by Michael Wonder on 09 Oct 2016
Teva and Celltrion announce exclusive biosimilar commercial partnership
6 October 2016 - Teva Pharmaceutical Industries Ltd and Celltrion Healthcare have announced that the companies have entered into an exclusive partnership to commercialise two of Celltrion’s mAb biosimilar candidates in the U.S. and Canada.
CT-P10 is a proposed mAb biosimilar to Rituxan (rituximab), which is used to treat patients with non-Hodgkin’s lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis, Wegener’s granulomatosis and microscopic polyangiitis (MPA).
CT-P6 is a proposed mAb biosimilar to Herceptin (trastuzumab), which is used for the treatment of HER2-overexpressing breast cancer and for the treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Combined annual net sales for Rituxan and Herceptin are approximately $6.5 billion in the U.S. and Canada.
